Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.91 - $1.88 $78,533 - $162,244
-86,300 Reduced 40.38%
127,400 $121,000
Q2 2024

Aug 15, 2024

BUY
$1.27 - $1.75 $110,744 - $152,600
87,200 Added 68.93%
213,700 $337,000
Q1 2024

May 07, 2024

BUY
$1.21 - $1.75 $124,630 - $180,250
103,000 Added 438.3%
126,500 $183,000
Q4 2023

Feb 14, 2024

SELL
$0.89 - $1.41 $2,136 - $3,384
-2,400 Reduced 9.27%
23,500 $31,000
Q3 2023

Nov 14, 2023

BUY
$1.08 - $1.85 $15,876 - $27,195
14,700 Added 131.25%
25,900 $36,000
Q2 2023

Aug 11, 2023

SELL
$0.96 - $1.4 $14,784 - $21,560
-15,400 Reduced 57.89%
11,200 $12,000
Q1 2023

May 16, 2023

BUY
$0.88 - $2.19 $3,080 - $7,665
3,500 Added 15.15%
26,600 $28,000
Q4 2022

Feb 14, 2023

SELL
$1.27 - $2.26 $31,750 - $56,499
-25,000 Reduced 51.98%
23,100 $35,000
Q3 2022

Nov 14, 2022

BUY
$1.41 - $2.79 $67,821 - $134,199
48,100 New
48,100 $102,000
Q1 2022

May 16, 2022

SELL
$1.91 - $3.98 $181,832 - $378,896
-95,200 Reduced 87.26%
13,900 $29,000
Q4 2021

Feb 14, 2022

SELL
$3.53 - $5.5 $197,327 - $307,450
-55,900 Reduced 33.88%
109,100 $405,000
Q3 2021

Nov 15, 2021

SELL
$4.99 - $6.55 $185,129 - $243,005
-37,100 Reduced 18.36%
165,000 $823,000
Q2 2021

Aug 11, 2021

BUY
$6.24 - $8.22 $302,640 - $398,670
48,500 Added 31.58%
202,100 $1.32 Million
Q1 2021

May 17, 2021

SELL
$6.74 - $10.95 $192,764 - $313,170
-28,600 Reduced 15.7%
153,600 $1.06 Million
Q4 2020

Feb 16, 2021

BUY
$3.75 - $10.56 $230,250 - $648,384
61,400 Added 50.83%
182,200 $1.86 Million
Q3 2020

Nov 16, 2020

SELL
$3.5 - $6.2 $223,650 - $396,180
-63,900 Reduced 34.6%
120,800 $423,000
Q2 2020

Aug 14, 2020

BUY
$2.16 - $5.46 $60,048 - $151,788
27,800 Added 17.72%
184,700 $922,000
Q1 2020

May 15, 2020

BUY
$1.46 - $7.19 $229,074 - $1.13 Million
156,900 New
156,900 $533,000

Others Institutions Holding PGEN

About PRECIGEN, INC.


  • Ticker PGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 208,150,000
  • Market Cap $171M
  • Description
  • Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...
More about PGEN
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.